Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses

Authors
Brandon McLeod, Moustafa T. Mabrouk, Kazutoyo Miura, ..., Neil P. King, Jonathan F. Lovell, Jean-Philippe Julien

Correspondence
jean-philippe.julien@sickkids.ca

In brief
Clinical development of transmission-blocking malaria vaccine Pfs48/45 antigens has been hindered by its poor biochemical characteristics. McLeod et al. utilized protein engineering techniques to improve the stability and biophysical properties of Pfs48/45-6C, which enhanced the inhibitory capacity of the immune response by 1–2 orders of magnitude, compared with the wild-type antigen across three vaccine platforms.

Highlights
- Combinatorial structure-based engineering of Pfs48/45-6C antigen improves its stability
- Thermostability and recombinant protein yield are increased over WT antigen
- 2.18 Å resolution crystal structure provides molecular insights into stability gain
- Multimerized stabilized antigens elicit potent transmission-reducing activity in vivo
Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses

Brandon McLeod,1,2 Moustafa T. Mabrouk,3 Kazutoyo Miura,4 Rashmi Ravichandran,5,6 Sally Kephart,7 Sophia Hailiemariam,1,2 Thao P. Pham,4 Anthony Semesi,1 Iga Kucharska,1 Prasun Kundu,1 Wei-Chiao Huang,3 Max Johnson,5,6 Alyssa Blackstone,5,6 Deleah Pettie,5,6 Michael Murphy,5,6 John C. Kraft,5,6 Elizabeth M. Leaf,5,6 Yang Jiao,3 Margy van de Vegte-Bolmer,6 Geert-Jan van Gemert,6 Jordache Ramjith,9 C. Richter King,10 Randall S. MacGill,10 Yimin Wu,10 Kelly K. Lee,7 Matthijs M. Jore,8 Neil P. King,5,6 Jonathan F. Lovell,3 and Jean-Philippe Julien1,2,11,12,*

1Program in Molecular Medicine, The Hospital for Sick Children Research Institute, 686 Bay Street, Toronto, ON M5G 0A4, Canada
2Department of Biochemistry, University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada
3Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA
4Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12735 Twinbrook Parkway, Rockville, MD 20852, USA
5Department of Biochemistry, University of Washington, Seattle, WA 98195, USA
6Institute for Protein Design, University of Washington, Seattle, WA 98195, USA
7Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195, USA
8Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands
9Radboud Institute for Health Sciences, Department for Health Evidence, Biostatistics Section, Radboud University Medical Center, Nijmegen, the Netherlands
10PATH’s Malaria Vaccine Initiative, 455 Massachusetts Avenue NW Suite 1000, Washington, DC 20001, USA
11Department of Immunology, University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada
12Lead contact
*Correspondence: jean-philippe.julien@sickkids.ca
https://doi.org/10.1016/j.immuni.2022.07.015

SUMMARY

Malaria transmission-blocking vaccines (TBVs) aim to elicit human antibodies that inhibit sporogonic development of Plasmodium falciparum in mosquitoes, thereby preventing onward transmission. Pfs48/45 is a leading clinical TBV candidate antigen and is recognized by the most potent transmission-blocking monoclonal antibody (mAb) yet described; still, clinical development of Pfs48/45 antigens has been hindered, largely by its poor biochemical characteristics. Here, we used structure-based computational approaches to design Pfs48/45 antigens stabilized in the conformation recognized by the most potently inhibitory mAb, achieving >25°C higher thermostability compared with the wild-type protein. Antibodies elicited in mice immunized with these engineered antigens displayed on liposome-based or protein nanoparticle-based vaccine platforms exhibited 1–2 orders of magnitude superior transmission-reducing activity, compared with immunogens bearing the wild-type antigen, driven by improved antibody quality. Our data provide the founding principles for using molecular stabilization solely from antibody structure-function information to drive improved immune responses against a parasitic vaccine target.

INTRODUCTION

Malaria is a major global health burden, with half the world population at risk of infection and 241 million confirmed cases in 2020 alone, resulting in more than 627,000 annual deaths predominantly in children (World Health Organization, 2021). Notwithstanding that substantial progress has been made in recent decades to reduce malaria incidence, this progress has largely slowed down in recent years, hastening the need for additional and innovative interventions (Talapko et al., 2019; World Health Organization, 2021). Malaria is caused by infection from vector-borne parasites of the genus Plasmodium, with the overwhelming majority of the clinical burden being driven by Plasmodium falciparum (Pf) (World Health Organization, 2021). A broadly effective malaria vaccine against Pf has remained elusive with only a single vaccine, RTS,S/AS01, having recently been approved for use after pilot implementation studies in Malawi, Ghana, and Kenya (The RTS S Clinical Trials Partnership, 2012; Duffy and Patrick Gorres, 2020; PAHO/WHO|Pan American Health Organization, 2021). RTS,S/AS01 is an anti-infection vaccine that aims to protect from parasite exposure. However, RTS,S/AS01 vaccine efficacy is modest,
and protection from severe disease falls below 35% after 1 year across age groups (White et al., 2015), highlighting a need for improved and complementary biomedical countermeasures against malaria.

The complexity of the Pf life cycle, featuring various stages that each present their own proteomic profile (Florens et al., 2002), is a challenge for the development of highly efficacious vaccines; however, it also presents a unique opportunity to target multiple essential proteins across life stages to curb the infection-transmission cycles within communities. Indeed, a previous study demonstrated the potential for synergistic inhibition of the Pf infection-transmission cycle when combining an anti-infective antibody with an antigen targeting the sexual stage of the parasite—the two mosquito vector-host bottlenecks of transmission (Sherrard-Smith et al., 2018). By targeting essential sexual stage antigens or mosquito antigens, transmission-blocking vaccines (TBVs) seek to induce antibodies in humans that are capable of blocking Pf transmission to Anopheles mosquito vectors (Miura et al., 2013; Delves et al., 2018; Acquah et al., 2019). In pre-clinical and clinical studies, TBVs have elicited strong antibody responses capable of greater than 90% transmission-reducing activity (TRA) in some humans (Healy et al., 2021) (NCT02334462, NCT03917654). Hence, TBVs have the potential to be used as an adjunct to anti-infective vaccines to help reduce malaria transmission and drive global elimination efforts (Brod et al., 2018).

The quest toward finding the best TBV antigen for vaccine development has in part been driven by monoclonal antibody (mAb) research (Julien and Wardemann, 2019). The most potent Pf transmission-blocking mAb yet identified is against Pfs48/45, with an IC80 (antibody concentration that gives 80% TRA) of ~1 µg/mL (Kundu et al., 2018). mAb TB31F is a humanized mAb with its parent elicited by whole gametocyte immunization in rats, and it is currently undergoing evaluation in a phase 1 clinical trial (NCT04238689) to determine its safety and Pf transmission-blocking potential in humans, with encouraging interim results (van der Boor et al., 2020). By contrast, the most potent mAbs reported to date against other clinical-stage TBVs have overall been substantially less potent (Pfs25: mAb 2544 has an IC80 of ~16 µg/mL [McLeod et al., 2019]; Pfs253: mAb LMIV230-01 required ~60 µg/mL to achieve ~80% TRA [Coelho et al., 2021]). Furthermore, it has been demonstrated that polyclonal antibody responses elicited in natural infection against Pfs48/45 can mediate transmission inhibition (Stone et al., 2016, 2018).

Pfs48/45 is a relatively conserved glycophaspatidylinositol (GPI)-linked protein expressed on the surface of gametes and is assumed to be essential for male gametocyte fertility (van Dijk et al., 2001). Developing a Pfs48/45-based TBV has proven challenging, largely due to the difficulties of recombinantly expressing Pfs48/45 in sufficient quality and quantity (Outchkovour et al., 2008). The most advanced Pfs48/45 antigen is genetically fused to the R0 protein for enhanced expression, folding, and stabilization of the Pfs48/45-6C domain (Outchkovour et al., 2008; Acquah et al., 2017; Singh et al., 2021). Although this antigen recently entered a phase 1 clinical trial (NCT04862416), it remains unclear whether stabilization of Pfs48/45 through fusion to another protein can be sufficient to elicit the most potent transmission-blocking activity against this target.

In this study, we evaluated whether structure-guided immunogen design—a computational approach that has previously been employed primarily to deliver improved antibody responses elicited by immunogens based on the fusion machinery of viral pathogens (McLellan et al., 2013; Pallesen et al., 2017)—could be utilized to stabilize the Pfs48/45-6C domain in its conformation recognized by the most potent transmission-blocking mAb, TB31F, and lead to improved TRA against malaria Pf. We report the design of stabilized Pfs48/45 antigens with improved expression yield and biochemical properties that elicit exquisitely potent malaria transmission-blocking activity. These findings highlight a transformative role for structure-based immunogen design and provide the founding principles of its use for parasitic vaccine targets.

RESULTS

Structure-based engineering improves Pfs48/45-6C stability

Structure-guided protein engineering efforts were undertaken to increase the thermostability of domain III, or the 6C domain, of Pfs48/45 based on its structure in complex with the most potent transmission-blocking mAb yet described, TB31F (Kundu et al., 2018; Figures 1A and 1B). Visual inspection (i.e., manually scanning through regions of the protein and assessing the molecular interactions of residues in their environment) of the crystal structure in Molecular Operating Environment (MOE) (Chemical Computing Group, 2022) identified 12 candidate residues for mutation outside the TB31F epitope that may stabilize the 6C fold. When recombinantly expressed and tested, only one mutation, G397L, notably increased the melting temperature (Tm) of the antigen by nearly 10 °C from 46.9 °C ± 2.5 °C to 55.5 °C ± 1.3 °C (Figure 1C). Encouraged by this finding, a model of 6C.G397L was used in conjunction with Rosetta (Das, and Baker, 2008) to further improve its thermostability. Among approximately 4,000 point mutations generated in silico, the majority of top-ranking stability mutations were concentrated in four distinct regions outside the TB31F epitope (Figure 1B). From this panel of in silico-identified mutations, seven 6C-single-antigen-engineered (“6C.sAgE”) constructs were generated and recombinantly expressed (Table 1). The variants exhibited a range of altered melting temperatures, with 6C.sAgE7 (G397L + H308Y) being the most improved with a Tm of 69.8 °C ± 0.3 °C (Figures 1C and 1D; Table 1). In addition to its marked improvement in melting temperature, 6C.sAgE7 also exhibited a reduced tendency to aggregate, eluting from size-exclusion chromatography (SEC) in a predominantly monodisperse peak in contrast to wild-type 6C (6C.WT), which contained a large quantity of higher-order misfolded oligomers (Figure 1E). In an accelerated thermostability study of 4 weeks (28 days) across three different temperatures (~20°C, 4°C, and 40°C) (Figure 1F), 6C.sAgE7 exhibited (1) no detectable loss of secondary structure, (2) no aggregation or degradation, and (3) no loss of binding to mAb TB31F, indicating that 6C.sAgE7 has an outstanding ability to maintain its stabilized structure even under prolonged thermal stress (Figures 1G, 1H, and S1). In brief, the engineered modifications made to 6C.sAgE7 substantially improved its overall biophysical characteristics.
The most stabilized Pfs48/45-6C antigen elicits antibodies that drive potent TRA

Next, we evaluated how these improved biophysical properties translated into immunogenicity and Pf TRA. Groups of six CD-1 mice were immunized with a 5 μg dose of differentially stabilized Pfs48/45-6C antigens (6C.WT, 6C.sAgE3, 6C.sAgE5, and 6C.sAgE7) adjuvanted with ISA720 and boosted at 21 days before sera were harvested on day 42 for evaluation (Figure 2A). In addition, the same Pfs48/45-6C antigens were formulated on the CoPoP multimerization platform (Huang et al., 2018) by binding His-tagged antigens to cobalt-containing “CPQ” immunogenic liposomes (Figure S2A), which also co-incorporate synthetic monophosphoryl lipid A and the saponin QS-21 as adjuvants. Antigen binding was associated with conserved overall CoPoP particle size as assessed by dynamic light scattering, with particle size remaining below 150 nm for all samples, and with a polydispersity index of less than 0.2, reflecting a relatively monodisperse population (Figure S2B). As determined by fluorescence energy transfer, labeled 6C.WT antigen rapidly bound to CoPoP
liposomes but not liposomes lacking cobalt within the porphyrin-phospholipid, and the liposome-displayed antigens maintained complexation stability over time during incubation with serum (Figures S2C and S2D).

Next, we investigated whether we could combine stability mutations from our top in silico predictions from our top two scoring combinations with experimentally validated hits to create a Pfs48/45-6C antigen with further improved biophysical characteristics over 6C.sAgE7. The 6C multiple antigen engineered 1 construct, or 6C.mAgE1, combined the 6C.sAgE7 mutations (G397L + H308Y) together with another highly ranked stabilizing mutation, I402V, whereas 6C.mAgE2 contained these three and two additional mutations based on their favorable biophysical characteristics as individual mutants and compatible co-localization in the antigen: S361R + D373S (Figures 3A–3C; Table 1). Both 6C.mAgE1 and 6C.mAgE2 had marginally improved thermostability from 6C.sAgE7, with $T_m$s of 72.2°C and 72.3°C, respectively (Figure 3D). However, recombinant expression of 6C.mAgE1 and 6C.mAgE2 by transient transfection in HEK293F cells resulted in drastic improvements in the yields of well-folded, secreted antigen in the supernatant, compared with less engineered antigens (Figure 3E); and >30-fold improvements in final yields after purification, compared with WT antigen; and >4-fold when compared with 6C.sAgE7 (Figure 3F).

The X-ray crystal structure of 6C.mAgE1 at 2.18 Å resolution was obtained and provides molecular insights into the combinatorial stabilizing potential of its mutations in Pfs48/45-6C (Table S1). The H308Y mutation allows increased van der Waals interactions with the nearby I393 residue and additionally puts a hydroxyl in H-bonding distance to D382, likely contributing to greater overall fold stability in this region (Figure 3B, inset I). The G397L mutation introduces a branched hydrocarbon side chain in a previously empty hydrophobic pocket, allowing for improved van der Waals contacts with neighboring residues N337, L339, E382, and V399 (Figure 3F). In an accelerated thermostability stress study, both 6C.mAgE1 and 6C.mAgE2 showed no signs of aggregation or degradation, further confirming their exquisite stability (Figure S1). Combined, these structural insights provide a molecular understanding for the improved biophysical and functional improvements of the engineered Pfs48/45-6C antigens.

**High TRA is associated with an extended Pfs48/45 antigenic surface**

With the improved biophysical characteristics associated with 6C.mAgE2, we next sought to evaluate whether presentation of the stabilized TB31F epitope alone was sufficient to achieve high-potency antibodies in immunization, or whether additional regions on Pfs48/45-6C stabilized in this particular antigenic conformation contributed to the potent inhibitory response. For this purpose, we introduced in 6C.mAgE2 four and six parameters for Pfs48/45-6C variants

| Pfs48/45-6C variant | Mutations | Rosetta score | $T_m$ (°C) | TB31F binding $K_D$ (nM) |
|---------------------|-----------|---------------|-------------|--------------------------|
| 6C.WT               | N/A       | N/A           | 46.9 ± 2.5  | 3.1 ± 2.3                |
| 6C.G397L            | G397L     | N/A           | 55.5 ± 1.3  | 5.4 ± 2.5                |
| 6C.sAgE1            | G397L, E365K | -66.72       | 53.5 ± 2.1  | 2.5 ± 1.8                |
| 6C.sAgE2            | G397L, S361R | -65.04       | 55.5 ± 0.7  | 3.3 ± 1.8                |
| 6C.sAgE3            | G397L, I402V | -63.32       | 56.3 ± 3.8  | 1.6 ± 0.6                |
| 6C.sAgE4            | G397L, D373S | -82.69       | 56.3 ± 0.8  | 1.8 ± 0.1                |
| 6C.sAgE6            | G397L, I398V | -72.15       | 58.3 ± 1.6  | 2.3 ± 0.2                |
| 6C.sAgE5            | G397L, I378V | -71.38       | 55.7 ± 2.9  | 2.1 ± 0.8                |
| 6C.sAgE7            | G397L, H308Y | -69.20       | 69.8 ± 0.3  | 1.1 ± 0.6                |
| 6C.mAgE1            | G397L, H308Y, I402V | N/A         | 72.2 ± 0.3  | 2.1 ± 0.1                |
| 6C.mAgE2            | G397L, H308Y, I402V, S361R, D373S | N/A         | 72.3 ± 0.7  | 2.0 ± 0.4                |

Among adjuvant groups, no significant differences in ELISA units (EUs) were observed ($p > 0.137$) between the various Pfs48/45-6C antigens, despite their differences in thermostability (Figure 2B). For the same antigen, EUs were significantly higher ($p < 0.011$) in the CPQ formulated groups compared with the ISA720 adjuvanted groups, except for 6C.sAgE3, for which only a higher trend was observed ($p = 0.095$). Overall, this data indicate that the formulation of Pfs48/45-6C constructs with CoPoP liposomes contributed to increased antibody titers (Figure 2B).

With the improved biophysical characteristics associated with 6C.mAgE2, we next sought to evaluate whether presentation of the stabilized TB31F epitope alone was sufficient to achieve high-potency antibodies in immunization, or whether additional regions on Pfs48/45-6C stabilized in this particular antigenic conformation contributed to the potent inhibitory response. For this purpose, we introduced in 6C.mAgE2 four and six parameters for Pfs48/45-6C variants

| Pfs48/45-6C variant | Mutations | Rosetta score | $T_m$ (°C) | TB31F binding $K_D$ (nM) |
|---------------------|-----------|---------------|-------------|--------------------------|
| 6C.WT               | N/A       | N/A           | 46.9 ± 2.5  | 3.1 ± 2.3                |
| 6C.G397L            | G397L     | N/A           | 55.5 ± 1.3  | 5.4 ± 2.5                |
| 6C.sAgE1            | G397L, E365K | -66.72       | 53.5 ± 2.1  | 2.5 ± 1.8                |
| 6C.sAgE2            | G397L, S361R | -65.04       | 55.5 ± 0.7  | 3.3 ± 1.8                |
| 6C.sAgE3            | G397L, I402V | -63.32       | 56.3 ± 3.8  | 1.6 ± 0.6                |
| 6C.sAgE4            | G397L, D373S | -82.69       | 56.3 ± 0.8  | 1.8 ± 0.1                |
| 6C.sAgE6            | G397L, I398V | -72.15       | 58.3 ± 1.6  | 2.3 ± 0.2                |
| 6C.sAgE5            | G397L, I378V | -71.38       | 55.7 ± 2.9  | 2.1 ± 0.8                |
| 6C.sAgE7            | G397L, H308Y | -69.20       | 69.8 ± 0.3  | 1.1 ± 0.6                |
| 6C.mAgE1            | G397L, H308Y, I402V | N/A         | 72.2 ± 0.3  | 2.1 ± 0.1                |
| 6C.mAgE2            | G397L, H308Y, I402V, S361R, D373S | N/A         | 72.3 ± 0.7  | 2.0 ± 0.4                |
non-native N-linked glycosylation sites (6C.mAgE2+4Gly and 6C.mAgE2+6Gly) to mask the majority of the surface of 6C.mAgE2 without interfering with the TB31F epitope (Figure 4A). As intended, addition of these immune-masking N-linked glycans did not impede folding of the antigens, which retained Tms greater than 60°C and high-affinity binding to TB31F (Figures S4C and S4D).

As above, mice were immunized twice with 5 μg of 6C.mAgE2, 6C.mAgE2+4Gly, or 6C.mAgE2+6Gly displayed on the CPQ liposome platform (Figure 2A). All groups elicited similarly high EU against 6C.sAgE7 (p = 0.646, Figure 4B). ELISA against 6C.mAgE2+6Gly and a TB31F epitope-knockout construct (6C.TB-KO) showed that sera elicited by 6C.mAgE2+4Gly and 6C.mAgE2+6Gly were proportionally significantly more reactive (p < 0.05) to 6C.mAgE2+6Gly than 6C.TB-KO, compared with sera from 6C.WT-, 6C.sAgE7-, or 6C.mAgE2-immunized animals (Figure S5), indicating 6C.mAgE2+4Gly and 6C.mAgE2+6Gly antisera recognized more the canonical TB31F epitope or newly introduced immune-masking-associated glycan epitopes. While the purified IgG from the 6C.mAgE2 group showed 100% TRA in SMFA at 375 μg/mL, purified IgG from the 6C.mAgE2+4Gly and 6C.mAgE2+6Gly groups dropped sharply to 86.6% and 38.3%, respectively (Figure 4C), indicating that the introduction of masking N-linked glycans across the antigenic surface of Pfs48/45-6C decreased the potency of the polyclonal response. These data imply that the TB31F epitope alone is not sufficient for potent transmission reduction.

To better understand the potency of the Pfs48/45 antigenic surface that surrounds the TB31F epitope, we next used a recently characterized mAb derived from natural infection, RUPA-117, which has an IC50 of approximately 10 μg/mL and binds to a nearby but distinct epitope from TB31F (Fabra-Garcia et al., 2021). Consistent with modeling suggesting that the additional glycans introduced in the hyperglycosylated constructs would impede binding to this recently discovered potent epitope, mAb RUPA-117 showed markedly reduced binding to 6C.mAgE2+4gly, and this binding was further perturbed for
Figure 3. Molecular insights provide basis for enhanced biochemical properties.
(A–C) Surface representation of (A) 6C.sAgE7, (B) 6C.mAgE1, and (C) 6C.mAgE2 with modeled N-linked glycans in teal, 6C.sAgE7 thermostability mutations in red, the I402V mutation in pale blue, and the S361R and D373S mutations in dark blue. The TB31F epitope is outlined in beige. Boxes zoom in on associated
(legend continued on next page)
6C.mAgE2+6Gly (Figure 4D). Taken together, our data demonstrate that an expanded antigenic surface on Pfs48/45 beyond the canonical TB31F epitope, but stabilized in the conformation recognized by TB31F, is best to elicit polyclonal sera with the strongest possible TRA.

**Engineered Pfs48/45-6C antigens elicit potent transmission-reducing antibodies across multimerization platforms**

Next, we sought to determine the extent to which the stabilized Pfs48/45-6C antigens could improve the potency of the elicited transmission-reducing antibody response, compared with the WT antigen. Purified IgG from mice immunized with 5 μg of 6C.WT, 6C.sAgE7, 6C.mAgE1, and 6C.mAgE2 displayed on the CPQ liposome platform (Figures 5A and 5B) was tested in SMFA experiments with serial dilutions ranging from 1,500 to 23 μg/mL. While all antibodies elicited by the engineered constructs with CPQ adjuvant showed almost complete inhibitions (>99% TRA) at 375 μg/mL, 6C.WT antibodies had a TRA of only 62.7% (95% CI, 20.4–81.6; p = 0.009) even at inhibitions (>99% TRA) at 375 μg/mL, 6C.mAgE2 to the HP ferritin protein nanocage (Figure 4D). Taken together, our data demonstrate potent TRA elicited by engineered Pfs48/45-6C constructs across several vaccine multimerization platforms.

**DISCUSSION**

Despite being the target of the most potent anti-malarial transmission-blocking mAb yet reported, Pfs48/45 has largely remained a challenging target for vaccine development. Its low recombinant expression and intrinsic instability have been the focus of various rescue strategies, including exploration of alternative expression systems, fusion proteins, and multimerization methods (Outchkourov et al., 2008; Acquah et al., 2017; Singh et al., 2021), all with mixed success. Structure-guided protein engineering has emerged as a viable strategy to stabilize antigens, most notably the fusion proteins of enveloped viruses. Prefusion-stabilizing mutations in the respiratory syncytial virus (RSV) F protein (McLellan et al., 2013) and in the MERS and SARS-CoV-2 spike proteins (Pallesen et al., 2017; Corbett et al., 2020; Hsieh et al., 2020) are salient examples of how stabilizing an antigen in the conformation associated with recognition by the most potent mAbs can generate immunogens eliciting enhanced neutralization responses, with demonstrated success for vaccine development. Here, we sought to investigate whether antigen stabilization as a strategy could extend beyond viral fusion glycoproteins and improve the functional immune response against a promising yet challenging antigen from the protozoan parasite *Plasmodium falciparum* (*P. falciparum*).

The Pfs48/45-stabilizing mutations we identified from in silico methods stabilize the Pfs48/45-6C fold recognized by
mAb TB31F by >25°C through a combination of filling hydrophobic pockets, introducing a new H-bond, and releasing steric strain. The higher stability achieved by our engineered Pfs48/45-6C constructs drastically improved transmission-blocking activity, compared with WT antigen, and led to polyclonal responses in mice with TRA IC₈₀ of ~40 µg/mL, approaching the exquisite potency of transmission-blocking mAb, TB31F, which has an IC₈₀ of ~1 µg/mL. This is especially noteworthy considering that the polyclonal antibodies were not affinity-purified, and therefore only a fraction of the antibodies are antigen-specific. This potency starkly contrasts with immune responses elicited by previously described Pfs48/45 constructs, which have demonstrated much lower and highly variable TRA across different studies and platforms, often with incomplete parasite inhibition even at ~750 µg/mL of purified polyclonal IgG or ~1/9 sera dilution (Singh et al., 2015, 2017, 2019; Lee et al., 2020). Our study thus provides an example of the transformative impact of structure-based immunogen design in the context of a parasitic vaccine target.
Figure 5. Pfs48/45-6C stabilized variants elicit responses associated with robust TRA across vaccine platforms

(A, D, and E) Schematic of (A) Pfs48/45-6C-CoPoP immunogens, (D) Pfs48/45-6C-I53-50 immunogens, and (E) Pfs48/45-6C-HpFerritin immunogens. The Pfs48/45-6C antigen is represented by a yellow diamond and colored as in Figure 3C. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and electron microscopy images of each multimerized 6C.mAgE2 immunogen are below its respective schematic (cryo-EM for 6C.mAgE2-CoPoP and negative-stain EM for 6C.mAgE2-I53-50 and 6C.mAgE2-HpFerritin), with “/C0” and “+” referring to non-reducing and reducing conditions, respectively, and I, B, and UB referring to input, bound, and unbound fractions of sample.

(B) ELISA units using 6C.sAgE7 as coated antigen for sera from immunization with stabilized Pfs48/45-6C variants formulated in CPQ. Data are plotted as individual mice (n = 6), with the bars representing the geometric mean.

(C) SMFA of serially diluted purified IgG derived from immunizations with CPQ-formulated 6C.WT (black), 6C.sAgE7 (red), 6C.mAgE1 (pale blue), and 6C.mAgE2 (blue). The best-estimate TRA (%) and 95% CI from multiple feeds are shown. The original SMFA results of each feed are in Tables S6 and S7.
Given that the exact biological function of Pfs48/45, and particularly the role of its 6C domain, remains poorly understood, why stabilization of this domain in this conformation leads to such drastically improved functional immune responses is not understood mechanistically at this time. Notably, as the vaccine-elicited titers did not considerably improve between the WT and engineered constructs, we conclude that the overall stabilization led to a substantial improvement in elicited antibody quality. Future work in gametocyte parasitology combined with structural biology on native Pfs48/45 and detailed characterization of the polyclonal antibody response will help define the mechanisms by which such potent parasite inhibition occurs. Nevertheless, our results showcase how antibody research, such as identifying the most potent mAbs, combined with high-resolution structural biology and structure-based design, can lead to improved immunogens capable of eliciting potent inhibitory responses—even in the absence of a complete understanding of the biological function for a target.

Here, we also investigated whether only the highly potent TB31F epitope or an extended antigenic surface on Pfs48/45-6C was crucial to elicit the most potent polyclonal antibody response. As sera elicited by hyperglycosylated 6C.mAgE2 constructs were substantially less potent in TRA, compared with the sera elicited by stabilized but non-hyperglycosylated immunogens, our data indicate that additional potent epitopes are present on Pfs48/45-6C beyond the TB31F epitope. Indeed, emerging data on human mAbs elicited during natural malaria infection identified that an antigenic surface adjacent to the TB31F epitope is also associated with recognition by potent antibodies (Fabra-Garcia et al., 2021). Our Pfs48/45-6C stabilization efforts emphasize the utility of whole-domain stabilization of antigens instead of more restricted immunogen design strategies, such as epitope grafting (Correia et al., 2014), particularly in the absence of knowledge derived from numerous inhibitory and non-inhibitory antibodies. Such a deep structure-function understanding of antibody recognition would be required to unlock the full spectrum of structure-based immunogen design approaches, and much remains to be uncovered in this regard for essential malaria antigens across parasite life stages (Julien and Wardemann, 2019).

Beyond antigen stabilization, vaccine formulation—both in terms of multivalent antigen display and adjuvant selection—is a major component of subunit vaccine design. Several display platforms exist and have been used for TBV antigen presentation, including genetic fusions and affinity linkages (Brod et al., 2018; Chichester et al., 2018; Mabrouk et al., 2020; Scaria et al., 2020, 2021; Jardine et al., 2013; Huang et al., 2018, 2020; Mabrouk et al., 2021). An advantage of the CPQ platform used in the present study is its ability to easily incorporate antigenic designs along with adjuvants for rapid immunogenicity screening. In this study, engineered constructs emerging from expression and biochemical characterization were directly associated on cobalt-containing liposomes via their His6x-tag and quickly evaluated iteratively in vivo to characterize the elicited immune responses, leveraging both multimerization and self-adjuvancement from the lipid content simultaneously as mechanisms to augment the immune response (Huang et al., 2018). We observed that antigenic display on diverse multimerization platforms provided an overall stronger antibody response across all malarial immunogens tested in this study, highlighting the importance of particular display in vaccine design. The potent polyclonal antibody response achieved here, independent of delivery platforms (i.e., across liposomes and two different protein nanocages with adjuvant), demonstrates that the quality of the antigen drives the quality of the immune response. The versatility of our stabilized antigens opens the door for optimizing methods of delivery, antigen display, and adjuvantation for advancing this promising engineered TBV immunogen toward evaluation in humans. Importantly, our engineered Pfs48/45 immunogen capable of eliciting exquisite inhibitory responses also enables future studies exploring combinations with leading immunogens across Pf life-stages, such as anti-infective PICSP-based vaccines, to deliver a multi-component malaria vaccine capable of achieving robust and durable malaria control and elimination.

Limitations of the study
The immunogenicity and functional data reported in this study are from murine immunizations and do not necessarily reflect the response that will be generated in a human IgG repertoire. Further studies are required to assess the degree to which the Pfs48/45 antigen stabilization described here will impart similar improvements to transmission-blocking activity in a human context. The SMFA experiments have an intrinsically large error, with low confidence in precise TRAs below 80% TRA without high replicates. Efforts were taken to reduce this effect via multiple replicate feeds, replicates with samples from separate immunizations, and transparent reporting of the data with full SMFA results (such as oocysts counts) included as supplemental information.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Mammalian cell lines and culture conditions

(F) Immunogenicity of Pfs48/45-6C variants fused to I53-50 and HpFerritin nanocages formulated in AddaVax as measured by ELISA titers against 6C.sAgE7-coated antigen. * and ** indicate p values of ≤0.05, or ≤0.01, respectively, as determined by one-way ANOVA for log-transformed ELISA titers. ELISA measurements for Figures 5B and 5F were performed in two different laboratories using separate methods; thus, ELISA units and ELISA titers are reported distinctly.

(G) SMFA with diluted pooled sera derived from mice immunized with 6C.WT, 6C.sAgE7, and 6C.mAgE2 fusions to I53-50, and 6C.mAgE2 fusion to HpFerritin, with samples colored as in (F). Values are calculated estimates from two independent SMFA experiments, and error bars indicate 95% confidence intervals. The original SMFA results of each feed are in Table S9 and calculated TRA estimates and p values in Table S10. See also Figure S6.
In vitro

We thank Marcos Miranda for electron microscopy of immuni.2022.07.015.

SUPPLEMENTAL INFORMATION

Global Scholar program (J.-P.J.), the Ontario Early Researcher Award program OPP1108403 from the Bill & Melinda Gates Foundation, the CIFAR Azrieli (OPP1179906 to J.-P.J.), PATH’s Malaria Vaccine Initiative under grant part, thanks to funding from the Bill and Melinda Gates Foundation

Canadian Institutes of Health Research Project grant (428410 to J.-P.J.); and in

endotoxin measurements for Pfs48/45-6C-I53-50 particles and controls

UV/vis for Pfs48/45-6C-I53-50 particles and controls

Protein purification of Pfs48/45-6C-I53-50 particles and controls

Expression and purification of Pfs48/45-6C-HpFerritin nanoparticle fusions

In vitro nanoparticle assembly and non-assembling control preparation

Endotoxin measurements for Pfs48/45-6C-I53-50 particles and controls

UV/vis for Pfs48/45-6C-I53-50 particles and controls

Protein purification of Pfs48/45-6C-I53-50A

Plasmid construction of Pfs48/45-6C-I53-50A

Transient transfection of Pfs48/45-6C-I53-50A

Protein purification of Pfs48/45-6C-I53-50A

Liposome preparation and characterization

Microbial protein expression and purification

Expression and purification of Pfs48/45-6C-HpFerritin nanoparticle fusions

In vitro nanoparticle assembly and non-assembling control preparation

Endotoxin measurements for Pfs48/45-6C-I53-50 particles and controls

UV/vis for Pfs48/45-6C-I53-50 particles and controls

Protein purification of Pfs48/45-6C-I53-50 particles and controls

Circular dichroism

Dynamic light scattering for extended thermostability analysis

Dynamic light scattering for Pfs48/45-6C-I53-50 particles and controls

Electron microscopy of CoPoP liposomes

Negative stain electron microscopy for Pfs48/45-6C-I53-50 particles and controls

Animal immunizations with Pfs48/45-6C and Pfs48/45-6C-CoPoP

Animal Immunizations of Pfs48/45-6C nanoparticles and controls

ELISA and SMFA of anti-Pfs48/45 antibodies elicited by Pfs48/45-6C and Pfs48/45-6C-CoPoP at Laboratory of Malaria and Vector Research (LMVR)

ELISA of antibodies elicited by Pfs48/45-6C nanoparticles and controls

SMFA at Radboud University Medical Center (RUMC)

METHOD DETAILS

In silico modeling of stabilized Pfs48/45-6C constructs

Recombinant protein expression and purification

Co-crystallization and structure determination

Hydrogen/Deuterium Exchange Mass Spectrometry

PLASMID CONSTRUCTION

Expression and purification of Pfs48/45-6C-HpFerritin nanoparticle fusions

In vitro nanoparticle assembly and non-assembling control preparation

Endotoxin measurements for Pfs48/45-6C-I53-50 particles and controls

UV/vis for Pfs48/45-6C-I53-50 particles and controls

Biolayer interferometry for Pfs48/45-6C variants

Biolayer interferometry for Pfs48/45-6C-I53-50 particles and controls

Circular dichroism

Dynamic light scattering for extended thermostability analysis

Dynamic light scattering for Pfs48/45-6C-I53-50 particles and controls

Electron microscopy of CoPoP liposomes

Negative stain electron microscopy for Pfs48/45-6C-I53-50 particles and controls

Animal immunizations with Pfs48/45-6C and Pfs48/45-6C-CoPoP

Animal Immunizations of Pfs48/45-6C nanoparticles and controls

ELISA and SMFA of anti-Pfs48/45 antibodies elicited by Pfs48/45-6C and Pfs48/45-6C-CoPoP at Laboratory of Malaria and Vector Research (LMVR)

ELISA of antibodies elicited by Pfs48/45-6C nanoparticles and controls

SMFA at Radboud University Medical Center (RUMC)

METHOD DETAILS

In silico modeling of stabilized Pfs48/45-6C constructs

Recombinant protein expression and purification

Co-crystallization and structure determination

Hydrogen/Deuterium Exchange Mass Spectrometry

PLASMID CONSTRUCTION

Expression and purification of Pfs48/45-6C-HpFerritin nanoparticle fusions

In vitro nanoparticle assembly and non-assembling control preparation

Endotoxin measurements for Pfs48/45-6C-I53-50 particles and controls

UV/vis for Pfs48/45-6C-I53-50 particles and controls

Biolayer interferometry for Pfs48/45-6C variants

Biolayer interferometry for Pfs48/45-6C-I53-50 particles and controls

Circular dichroism

Dynamic light scattering for extended thermostability analysis

Dynamic light scattering for Pfs48/45-6C-I53-50 particles and controls

Electron microscopy of CoPoP liposomes

Negative stain electron microscopy for Pfs48/45-6C-I53-50 particles and controls

Animal immunizations with Pfs48/45-6C and Pfs48/45-6C-CoPoP

Animal Immunizations of Pfs48/45-6C nanoparticles and controls

ELISA and SMFA of anti-Pfs48/45 antibodies elicited by Pfs48/45-6C and Pfs48/45-6C-CoPoP at Laboratory of Malaria and Vector Research (LMVR)

ELISA of antibodies elicited by Pfs48/45-6C nanoparticles and controls

SMFA at Radboud University Medical Center (RUMC)

QUANTIFICATION AND STATISTICAL ANALYSIS

Supplemental information can be found online at https://doi.org/10.1016/j.immuni.2022.07.015.
Adults. Vaccine blocking vaccine against malaria: a phase 1 dose-escalation study in healthy immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission Chichester, J.A., Green, B.J., Jones, R.M., Shoji, Y., Miura, K., Long, C.A., Lee, Duffy, P.E., and Patrick Gorres, J. (2020). Malaria vaccines since 2000: prog-

Lyophilized, antigen-bound liposomes with reduced MPLA and enhanced thermostability. Int. J. Pharm. 589, 119843.

Miura, K., Chiem, K., Rujas, E., Huang, W.C., Jahagirdar, D., Quinn, B., Surendran Nair, M., Nissly, R.H., Caveren, V.S., Boyle, N.R., et al. (2021). Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protec-
tive immunity against SARS-CoV-2 in mice. Sci. Adv. 7, 1476.

Marr, C.R., Benlekbir, S., and Rubinstein, J.L. (2014). Fabrication of carbon films with ~500nm holes for cryo-EM with a direct detector device. J. Struct. Biol. 185, 42–47.

McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674.

Mcelhanon, J.S., Chen, M., Joyce, M.G., Sastry, M., Stewart-Jones, G.B., Yang, Z., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013). Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592–598.

McLeod, B., Miura, K., Scally, S.W., Bosch, A., Nguyen, N., Shin, H., Kim, D., Volkumth, W., Ramisch, S., Chichester, J.A., et al. (2019). Potent antibody line-
age against malaria transmission elicited by human vaccination with Pfs25. Nat. Commun. 10, 4328.

Miura, K., Deng, B., Wu, Y., Zhou, L., Pham, T.P., Diouf, A., Wu, C.K., Lee, S.M., Plieskatt, J.L., Morin, M.J., et al. (2019). ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum. Vaccine 37, 2073–2078.

Miura, K., Orcutt, A.C., Muratova, O.V., Miller, L.H., Saul, A., and Long, C.A. (2008). Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26, 193–200.

Miura, K., Swhihart, B.J., Deng, B., Zhou, L., Pham, T.P., Diouf, A., Burton, T., Fay, M.P., and Long, C.A. (2016). Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay. Vaccine 34, 4145–4151.

Miura, K., Deng, B., Tullo, G., Diouf, A., Morezt, S.E., Locke, E., Morin, F., Fay, M.P., and Long, C.A. (2013). Qualification of standard membrane-feeding assay with plasmodium falciparum malaria and potential improvements for future assays. PLoS one 8, e57909.

Morin, A., Eisenbraun, B., Key, J., Sanschagrin, P.C., Timony, M.A., Ottaviano, M., and Sliz, P. (2013). Collaboration gets the most out of software. eLife 2, e01456.

Ouchtourov, N.S., Roefen, W., Kaan, A., Jansen, J., Luty, A., Schuffel, D., van Gemert, G.J., van de Vege-Bolmer, M., Sauerwein, R.W., and Stunnenberg, H.G. (2008). Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc. Natl. Acad. Sci. USA 105, 4301–4305.

PAHO/WHO|Pan American Health Organization (2021). Technical Note: malaria vaccine and priorities for malaria elimination in the Americas. https://www.paho.org/en/documents/technical-note-malaria-vaccine-and-priorities-malaria-elimination-americas.

Pallesen, J., Wang, N., Corbett, K.S., Wrapp, D., Kirchdoerfer, R.N., Turner, H.L., Cottrell, C.A., Becker, M.M., Wang, L., Shi, W., et al. (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. USA 114, E7348–E7357.

Ponnudurai, T., Lensen, A.H., Van Gemert, G.J., Bensink, M.P., Bolmer, M., and Meuwissen, J.H. (1989). Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology 98, 165–173.
Scaria, P.V., Anderson, C., Muratova, O., Alani, N., Trinh, H.V., Nadakal, S.T., Zaidi, I., Lambert, L., Beck, Z., Barnafo, E.K., et al. (2021). Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques. npj Vaccines 6, 148.

Scaria, P.V., Chen, B.B., Rowe, C.G., Alani, N., Muratova, O.V., Barnafo, E.K., Lambert, L.E., Zaidi, I.U., Lees, A., Rausch, K.M., et al. (2020). Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230. Vaccine 38, 5480–5489.

Sherrard-Smith, E., Sala, K.A., Betancourt, M., Upton, L.M., Angrisano, F., Morin, M.J., Ghan, A.C., Churcher, T.S., and Blagborough, A.M. (2018). Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density. eLife 7, e35213.

Singh, S.K., Roeffen, W., Andersen, G., Bousema, T., Christiansen, M., Sauerwein, R., and Theisen, M. (2015). A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies. Vaccine 33, 1981–1986.

Singh, S.K., Thrane, S., Janitzek, C.M., Nielsen, M.A., Theander, T.G., Theisen, M., Salanti, A., and Sander, A.F. (2017). Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display. Vaccine 35, 3726–3732.

Singh, S.K., Thrane, S., Chourasia, B.K., Teelen, K., Graumans, W., Stoter, R., van Gemert, G.J., van de Vegte-Bolmer, M.G., Nielsen, M.A., Salanti, A., et al. (2019). Pfs230 and Pfs48/45 fusion proteins elicit strong transmission-blocking antibody responses against plasmodium falciparum. Front. Immunol. 10, 1256.

Singh, S.K., Pleskatt, J., Chourasia, B.K., Fabra-Garcia, A., Garcia-Senosian, A., Singh, V., Bengtsson, K.L., Reimer, J.M., Sauerwein, R., Jore, M.M., and Theisen, M. (2021). A reproducible and scalable process for manufacturing a Pfs48/45 based Plasmodium falciparum transmission-blocking vaccine. Front. Immunol. 11, 3369.

Stone, W.J.R., Campo, J.J., Ouédraogo, A.L., Meierstein-Kessel, L., Morlais, I., Da, D., Cohuet, A., Nasng, S., Sutherland, C.J., van de Vegte-Bolmer, M., et al. (2018). Unravelling the immune signature of Plasmodium falciparum transmission-reducing immunity. Nat. Commun. 9, 558.
## STAR★METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| TB31F               | Kundu et al. (2018) | N/A        |
| RUPA-47             | This paper | N/A        |
| RUPA-117            | This paper | N/A        |
| anti-mouse horseradish peroxidase-conjugated horse IgG | Cell Signaling Technology | Cat#7076S |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| 6C.WT               | Kundu et al. (2018) | N/A        |
| 6C.sAgE1            | This paper | N/A        |
| 6C.sAgE2            | This paper | N/A        |
| 6C.sAgE3            | This paper | N/A        |
| 6C.sAgE4            | This paper | N/A        |
| 6C.sAgE5            | This paper | N/A        |
| 6C.sAgE6            | This paper | N/A        |
| 6C.sAgE7            | This paper | N/A        |
| 6C.mAgE1            | This paper | N/A        |
| 6C.mAgE2            | This paper | N/A        |
| 6C.TB-KO            | This paper | N/A        |
| 6C.mAgE2-4Gly       | This paper | N/A        |
| 6C.mAgE2-6Gly       | This paper | N/A        |
| CoPoP Liposomes     | Huang et al. (2018) | N/A        |
| I53-50B             | Brouwer et al. (2019) | N/A        |
| Pfs48/45-6C.sAgE7-I53-50A | This paper | N/A        |
| Pfs48/45-6C.mAgE1-I53-50A | This paper | N/A        |
| Pfs48/45-6C.mAgE2-I53-50A | This paper | N/A        |
| **Critical commercial assays** |        |            |
| Ni-NTA biosensors   | ForteBio | Cat#18-5102 |
| Anti-human Fab-CH1 biosensors | ForteBio | Cat#18-5125 |
| Anti-penta-HIS biosensors | Sartorius | Cat# 18-5120 |
| 10 well 4-20% gradient SDS-PAGE gel | Bio-Rad | Cat#4561096 |
| 10x Tris/Glycine/SDS Buffer | Bio-Rad | Cat#1610732 |
| Precision Plus Dual Colour Standards | Bio-Rad | Cat#1610394 |
| Novex 4-12% bis-tris acrylamide gels | Invitrogen | Cat#NP0321BOX |
| MES Running Buffer | Invitrogen | Cat#NP0002 |
| **Deposited data** |        |            |
| Crystal structure of 6C.mAgE1-RUPA-47 Fab complex | This paper | PDB: 7UNB |

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Experimental models: Cell lines** | | |
| FreeStyle™ 293-F Cells | Thermo Fisher Scientific | Cat#R79007 |
| Exp293F GnTI − /− Cells | Thermo Fisher Scientific | A39240 |
| Lemo21(DE3) | NEB | Cat#C2528J |
| **Experimental models: Organisms/strains** | | |
| Mouse: Crl:CD1(ICR) | Charles River Laboratories | Strain Code 022 |
| Parasite: P. falciparum ; NF54 strain | Miura et al. (2013) | N/A |
| Mosquito: Anopheles stephensi (Nijmegen strain) | Ponnudurai et al. (1989) | N/A |
| **Recombinant DNA** | | |
| pcDNA3.4_6C.WT-His | Kundu et al. (2018) | N/A |
| pcDNA3.4_TB31F_HC | Kundu et al. (2018) | N/A |
| pcDNA3.4_TB31F_LC | Kundu et al. (2018) | N/A |
| pcDNA3.4_RUPA-117_HC | This Paper | N/A |
| pcDNA3.4_RUPA-117_KC | This Paper | N/A |
| pcDNA3.4_RUPA-47_HC | This Paper | N/A |
| pcDNA3.4_RUPA-47_KC | This Paper | N/A |
| pcDNA3.4_6C.sAgE1-His | This Paper | N/A |
| pcDNA3.4_6C.sAgE2-His | This Paper | N/A |
| pcDNA3.4_6C.sAgE3-His | This Paper | N/A |
| pcDNA3.4_6C.sAgE4-His | This Paper | N/A |
| pcDNA3.4_6C.sAgE5-His | This Paper | N/A |
| pcDNA3.4_6C.sAgE6-His | This Paper | N/A |
| pcDNA3.4_6C.sAgE7-His | This Paper | N/A |
| pcDNA3.4_6C.mAgE1-His | This Paper | N/A |
| pcDNA3.4_6C.mAgE2-His | This Paper | N/A |
| pcDNA3.4_6C.mAgE2+4Gly-His | This paper | N/A |
| pcDNA3.4_6C.mAgE2+6Gly-His | This paper | N/A |
| I53-50B | Brouwer et al. (2019) | N/A |
| Pfs48/45-6C.sAgE7-I53-50A | This paper | N/A |
| Pfs48/45-6C.mAgE1-I53-50A | This paper | N/A |
| Pfs48/45-6C.mAgE2-I53-50A | This paper | N/A |
| **Software and algorithms** | | |
| Rosetta | Das and Baker (2008) | https://www.rosettacommons.org/software |
| Phenix | Adams et al. (2010) | http://www.phenix-online.org/ |
| XDS | Kabsch (2010) | https://xds.mpig.de/html_doc/downloading.html |
| Coot | Emsley et al. (2010) | https://ww2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/ |
| PRISM Graphpad | GraphPad Software, LLC | https://www.graphpad.com/scientific-software/prism/ |
| Molecular Operating Environment | Chemical Computing Group, LLC | https://www.chemcomp.com/index.htm |
| **Other** | | |
| Ni-NTA Magnetic Beads | Thermo Fischer Scientific | Cat#88831 |
| Magnetic Separator | Thermo Fischer Scientific | Cat#12321D |
| Homemade holey gold grids | Marr et al. (2014) | N/A |
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Jean-Philippe Julien (jean-philippe.julien@sickkids.ca).

Materials availability
All unique and stable reagents generated in this study are available via the lead contact upon a reasonable request.

Data and code availability
- The crystal structure has been deposited to the Protein Data Bank and is publicly available as of the date of publication. Accession numbers are listed in the key resources table.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mammalian cell lines and culture conditions
For recombinant protein expression, female mammalian cells (HEK 293F, FreeStyle™ 293-F cells, Thermo Fisher Scientific; HEK 293S, Gnt I−/− cells, ATCC) were cultured in suspension in Gibco™ FreeStyle™ 293 Expression Medium (Thermo Fisher Scientific) for 5-7 days at 37°C, with 70% humidity and 8% CO2 and rotating at 150 RPM.

Mice
Naïve female ICR mice were maintained in a specific pathogen-free vivarium, housed in a climate-controlled room on a 12-hour day/night cycle, and had access to food and water ad libitum. Immunizations of the mice occurred between six to eight weeks of age, and groups of mice were randomly populated. Animal protocols involving these mice were approved and performed in accordance with the Institutional Animal Care and Use Committee at University at Buffalo. 8-week female Crl:CD1(ICR) mice were also used in this study and were randomly assigned across experimental groups. Animal protocols involving these mice followed the National Institute of Health’s Guideline for the Care and Use of Laboratory Animals and were approved by the University of Washington’s Institutional Animal Care and Use Committee.

METHOD DETAILS

In silico modeling of stabilized Pfs48/45-6C constructs
The 6CG397L model was generated by visualization of the previous Pfs48/45-6C-TB31F Fab complex crystal structure (PDB ID: 6E63). This structure was prepared using QuickPrep in MOE, and models were generated through MOE’s residue scanning function (Chemical Computing Group, 2022). Predicted stability changes were determined by model generation using MOE’s scoring algorithms (Chemical Computing Group, 2022). Next, the pmut function in the Rosetta Modelling suite was used to design the 6C.sAgE series of double stability mutations, by mutating every residue on the 6CG397L structure and scoring the resulting constructs by intrinsic stability (Das and Baker, 2008). The top 500 were manually sorted based on which region of the antigen they mapped to. The top five mutations from each region were analyzed by visual inspection and the most promising candidates were chosen for construct design and recombinant expression.

Recombinant protein expression and purification
All Pfs48/45-6C antigen variants were based on consensus 3D7 sequence, gene synthesized and cloned into the pcDNA3.4 expression vector (GeneArt). Antigens were transiently expressed in HEK293F cells (ThermoFisher Scientific) and purified using a 5 mL HisTrap FF column (GE Healthcare), followed by size exclusion chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare). 6C.TB-KO was generated by analyzing the TB31F-6C structure (PDB ID: 6E63), and mutating a key residue involved in the antigen-antibody interaction (K416D) to knock-out TB31F binding. 6C.mAgE2+4Gly and 6C.mAgE2+6Gly were designed using visual inspection of the same structure, and inserting N-linked glycosylation sequons into regions that would not be expected to perturb TB31F binding (6C.mAgE2+4Gly: K307N, L318N, D320T, D380N, E382T, K404N; 6C.mAgE2+6Gly: K307N, L318N, D320T, L339T, E362N, L364T, D380N, E382T, K404N)

All Fabs were transiently expressed in HEK293F cells (ThermoFisher Scientific) and purified as previously described (Kundu et al., 2018; McLeod et al., 2019). Briefly, LambdaSelect or KappaSelect affinity (GE Healthcare) and size exclusion (Superdex 200 Increase 10/300 GL, GE Healthcare) chromatography columns were used; for some Fabs, cation exchange (MonoS, GE Healthcare) was also used to achieve higher purity.
Co-crystallization and structure determination
6C.mAgE1, RUPA-117 Fab, and RUPA-47 Fab were complexed at a 1:1:5:1.5 ratio to form a ternary complex. The antigen-Fab-Fab ternary complex was separated from excess Fab by size exclusion chromatography using a Superdex 200 Increase column (GE Healthcare). The resulting 6C-RUPA-117-RUPA-47 complex was concentrated to 7.5 mg/mL. Setting-drop crystallization trays for the 6C-RUPA-47-RUPA-117 complex were set up at 2:1:2 ratio of protein complex, seeds, and reservoir solution. 6C-RUPA-117-RUPA-47 crystals grew in 0.2 M magnesium chloride, 25 % (w/v) polyethylene glycol 3350, and 0.1 M Tris, pH 8.5. Well-differacting crystals for 6C.mAgE2 in complex with Fab could not be obtained. Data were collected on the 23ID beamline at the Advanced Photon Source (APS), and subsequently processed using XDS and Xprep (Kabsch, 2010). Phaser was used for molecular replacement with Pfs48/45-6C (PDB ID: 6E63) and Fab from our internal database as search models (McCoy et al., 2007). Resulting structures were built and refined using phenix.refine (Adams et al., 2010) and Coot (Emsley et al., 2010), accessed through SBGrid (Morin et al., 2013).

Hydrogen/Deuterium Exchange Mass Spectrometry
Samples were prepared using 120 pmol (2 μg) of protein incubated in deuterated buffer (150 mM NaCl, 20 mM Na₂PO₄, 0.02% sodium azide, 85% D₂O, pH 7.66) for 3 s, 1 min, 30 min, and 5 h at room temperature. The reaction was stopped by adding an equal volume of ice-cold quench buffer (200 mM tris)-2-chorenethyl) phosphate (TCEP), 0.2% formic acid) to a final pH of 2.5. Samples were immediately frozen with liquid nitrogen and stored at -80 °C until analysis. Undeuterated controls were prepared similarly but using optima water in place of D₂O. The zero-time point was made by adding the protein directly to quenched deuteration buffer before freezing. Fully deuterated controls were prepared by collecting pepsin digestion eluate from two undeuterated samples. The digested peptides were concentrated under vacuum, suspended in deuteration buffer, and heated to 65 °C for one hour before they were subsequently quenched and frozen. To monitor protein stability during the longest exchange reaction, a 3 s pulse was performed alongside the 5 h time point. All exchanges were performed in triplicate.

As previously described, samples were thawed on ice and digested using an online pepsin column kept at 20 °C (Verkerke et al., 2016). The peptic peptides were resolved over a Waters ACQUITY UPLC CSH C18 VanGuard, 130 Å, 1.7 μm, 1 mm by 100 mm column using a 15 min linear gradient and analyzed on a Waters Synapt G2-Si Q-TOF mass spectrometer with ion mobility enabled (Verkerke et al., 2016). Peptide assignments were made from MSE data collected for undeuterated samples using Byonic (Version 3.8, Protein Metrics Inc.). Deuterium uptake analysis was performed with HD-Examiner (Sierra Analytics) and HX-Express v2 for binomial fitting (Weis et al., 2006; Guttmann et al., 2013). The percent exchange was normalized to the fully deuterated sample and corrected for in-exchange using the zero timepoint. Internal exchange standards [Pro-Pro-Pro-Ile [PPPI] and Pro-Pro-Pro-Phe [PPPFP]] were included in each reaction to ensure that conditions were consistent throughout the experiment. Data for each timepoint was collected in duplicate.

Plasmid construction of Pfs48/45-6C-I53-50A
The Pfs48/45-6C variants were genetically fused to the N terminus of the trimeric I53-50A nanoparticle component using a linker of 8 glycine and serine residues. Pfs48/45-6C-8GS-I53-50A fusions were synthesized and cloned by Genscript into pCMV with an N-terminal secrecon signal peptide and a C-terminal hexa-histidine tag.

Transient transfection of Pfs48/45-6C-I53-50A
Pfs48/45-6C-I53-50A proteins were produced in Expi293F cells grown in suspension using Expi293F expression medium (Life Technologies) at 33 °C, 70% humidity, 8% CO₂ rotating at 150 rpm. The cultures were transfected using PEI-MAX (Polyscience) with cells grown to a density of 3.0 million cells per mL and cultivated for 3 days. supernatants were clarified by centrifugation (5 min at 4000 x g), the addition of PDADMAC solution to a final concentration of 0.0375% (Sigma Aldrich, #409014), and a second spin (5 min at 4000 x g).

Protein purification of Pfs48/45-6C-I53-50A
Proteins containing His tags were purified from clarified supernatants via an AKTA AVANT FPLC using prepacked 5mL Ni Sepharose excel resin columns (Cytiva), with each clarified supernatant was supplemented with 1 M Tris-HCl pH 8.0 to a final concentration of 45 mM and 5 M NaCl to a final concentration of ~310 mM, prior to column application. The resin was washed with 5 column volumes (CV) of 20 mM Tris pH 7.0, 150 mM NaCl, and the protein was eluted over 10CV column up to 100%B buffer, which was composed of 20 mM Tris pH 7.0, 150 mM NaCl, 500 mM imidazole. SDS-PAGE was used to assess the purity of peak fractions of interest. IMAC elutions were concentrated to ~2mL in a hydrated 10K molecular weight cutoff dialysis cassette (Millipore). Samples were then further purified by sizing on a Superdex S200 Increase 10/30 GL (Cytiva) in PBS + 5% glycerol. Peak fractions were pooled and analyzed by SDS-PAGE and Octet and measured for endotoxin content before freezing in single-use aliquots stored at -80°C.

Liposome preparation and characterization
CoPoP/PHAD/QS-21 liposomes had a [DOPC:CHOLO:PLA2:CoPoP:QS-21] mass ratio of [20:5:0.4:1:0.4]. Liposomes were prepared as previously described using ethanol injection and nitrogen pressurized lipid extrusion in PBS, carried out at 50°C (Mabrouk et al., 2020). Ethanol was then removed by dialysis against PBS twice at 4°C. QS-21 (1 mg/mL) was added to the liposomes after formation at an equal mass ratio as PHAD. The final liposome concentration was adjusted to 320 mg/mL CoPoP, and liposomes were sterile.
filtered and stored at 4°C. Liposome sizes were determined by dynamic light scattering (DLS) with a NanoBrook 90 plus PALS instrument after 200-fold dilution in PBS.

To assess the stability of constructs of interest bound in particle form, a Ni-NTA competition assay was carried out as previously described (Mabrouk et al., 2021). Ni-NTA magnetic beads (ThermoFisher Scientific, catalog no. 88831) were added to the liposome-incubated Pfs48/45 constructs (1:4 mass ratio of total protein:CoPoP) and incubated with the beads for 30 min at RT, then the supernatant and beads were separated using a magnetic separator (ThermoFisher Scientific, catalog no. 12321D). Denaturing reducing loading dye was then added to the samples (supernatant or beads) and heated at 95°C for 10 min. The samples were then subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using Novex 4 to 12% bis-tris acrylamide gels (Invitrogen, catalog no. NP0321BOX) and MES running buffer (Invitrogen, catalog no. NP0002).

To determine the binding kinetics and stability of protein-liposomes, Pfs48/45 constructs were labeled with DY-490-SE (Dyomics) with a molar ratio of 5:1 dye to Pfs48/45 construct. The reaction was done in 50 mM sodium bicarbonate buffer (pH 9) and incubated with shaking for 1 h at room temperature. Free dye was removed by dialysis against PBS overnight at 4°C. Binding kinetics of labeled Pfs48/45 constructs was monitored as a function of fluorescence quenching effect due to the proximity of the dye to the porphyrin ring after binding to CoPoP liposomes but not PoP liposomes resulting in energy transfer from the dye to the porphyrin over a 3 h period. Serum stability of bound labeled constructs was tested in the same manner where after incubation for 3 h, the pre-bound protein/liposomes were transferred into 20% serum in PBS and kept shaking at 37°C over the following 24 h where the fluorescence was monitored. The binding to liposomes was calculated by the following equation:

\[ \text{Pfs48/45 - DY - 490 binding } \% = \left[ 1 - \left( \frac{F_{\text{Incubated sample}}}{F_{\text{Pfs48/45 - DY - 490 in PBS}}} \right) \right] \times 100\% \]

The fluorescence was read at excitation/emission 480/551 nm in a microplate reader (TECAN Safire).

**Microbial protein expression and purification**

The IS3-50B.4.PT1 and 2obx proteins were expressed in Lemo21(DE3) (NEB) in LB (10 g Tryptone, 5 g Yeast Extract, 10 g NaCl) grown in 2 L baffled shake flasks or a 10 L BioFlo 320 Fermenter (Eppendorf). Cells were grown at 37°C to an OD600 ~0.8, and then induced with 1 mM IPTG. Expression temperature was reduced to 18°C and the cells shaken for ~16 h. The cells were harvested and lysed by microfluidization using a Microfluidics M110P at 18,000 psi in 50 mM Tris, 500 mM NaCl, 30 mM imidazole, 1 mM PMSF, 0.75% CHAPS. Lysates were clarified by centrifugation at 24,000 g for 30 min and applied to a 2.6 cm × 10 cm Ni Sepharose 6 FF column (Cytiva) for purification by IMAC on an AKTA Avant150 FPLC system (Cytiva). Protein of interest was eluted over a linear gradient of 30 mM to 500 mM imidazole in a background of 50 mM Tris pH 8, 500 mM NaCl, 0.75% CHAPS buffer. Peak fractions were pooled, concentrated in 10K MWCO centrifugal filters (Millipore), sterile filtered (0.22 μm) and applied to either a Superdex 200 Increase 10/300, or HiLoad S200 pg GL SEC column (Cytiva) using 50 mM Tris pH 8, 500 mM NaCl, 0.75% CHAPS buffer. IS3-50B.4PT1 and 2obx elute at ~0.45 CV. After sizing, bacterial-derived components were tested to confirm low levels of endotoxin before using for nanoparticle assembly.

**Expression and purification of Pfs48/45-6C-HpFerritin nanoparticle fusions**

Pfs48/45-6C-HpFerritin nanoparticle fusions containing the following mutations from native Hp ferritin sequence (K75N, E77T, E99N, and 1101T; and addition of a PADRE sequence (Alexander et al., 1994) at the C-terminus: AKFVAAWTLKAAA) were transiently expressed in HEK293S (Gnt I -/-) cells (ThermoFisher Scientific), and purified using a StrepTrap HP (GE Healthcare) column, followed by TEV cleavage for tag removal. Ferritin fusion nanocages were further purified to size homogeneity on a Superose 6 Increase 10/300 GL column (GE Healthcare). To verify their integrity by negative stain electron microscopy, 6C.mAgE2-HpFerritin nanoparticles were grown in 2 L baffled shake flasks or a 10 L BioFlo 320 Fermenter (Eppendorf). Cells were grown at 37°C to an OD600 ~0.8, and the cells shaken for ~24 h where the fluorescence was monitored. The binding to liposomes was calculated by the following equation:

\[ \text{Pfs48/45 - DY - 490 binding } \% = \left[ 1 - \left( \frac{F_{\text{Incubated sample}}}{F_{\text{Pfs48/45 - DY - 490 in PBS}}} \right) \right] \times 100\% \]

The fluorescence was read at excitation/emission 480/551 nm in a microplate reader (TECAN Safire).

**In vitro nanoparticle assembly and non-assembling control preparation**

Total protein concentration of purified individual nanoparticle components was determined by measuring absorbance at 280 nm using a UV/vis spectrophotometer (Agilent Cary 8454) and calculated extinction coefficients (Gasteiger et al., 2005). The assembly steps were performed at room temperature with addition in the following order: Pfs48/45-6C-I53-50A trimeric fusion protein, followed by additional buffer as needed to achieve desired final concentration, and finally I53-B.4PT1 pentameric component or 2obx non-assembling control (in 50 mM Tris pH 8, 500 mM NaCl, 0.75% w/v CHAPS), with a molar ratio of Pfs48/45-6C-I53-50A: I53-B.4PT1 (or 2obx) of 1:1.1. All in vitro assemblies and non-assembling control preparations were incubated at 2–8°C with gentle rocking overnight before purification by SEC on a Superose 6 Increase 10/300 GL column in order to remove the residual unassembled component. Non-assembling controls were not SEC purified after preparation at the 1:1 molar ratio. Assembled nanoparticles were sterile filtered (0.22 μm) immediately prior to column application and following pooling of fractions.

**Endotoxin measurements for Pfs48/45-6C-I53-50 particles and controls**

Endotoxin levels in protein samples were measured using the EndoSafe Nexgen-MCS System (Charles River). Samples were diluted 1:50 or 1:100 in Endotoxin-free LAL reagent water and applied into wells of an EndoSafe LAL reagent cartridge. Charles River EndoScan-V software was used to analyze endotoxin content, automatically back-calculating for the dilution factor. Endotoxin
UV/vis for Pfs48/45-6C-I53-50 particles and controls
Ultraviolet-visible spectrophotometry (UV/vis) was measured using an Agilent Technologies Cary 8454. Samples were applied to a 10 mm, 50 μL quartz cell (Starna Cells, Inc.) and absorbance was measured from 180 to 1000 nm. Net absorbance at 280 nm, obtained from the measurement and single reference wavelength baseline subtraction, was used with calculated extinction coefficients and molecular weights to obtain protein concentration. The ratio of absorbance at 320/280 nm was used to determine relative aggregation levels in real-time stability study samples. Samples were diluted with respective purification/instrument blanking buffers to obtain an absorbance between 0.1 and 1.0. All data produced from the UV/vis instrument was processed in the 845x UV/visible System software.

Biolayer interferometry for Pfs48/45-6C-I53-50 particles and controls
Biolayer interferometry (Octet RED96, ForteBio) experiments at 25 °C were conducted to determine the binding kinetics of Pfs48/45-6C-I53-50 particles and the TB31F Fab. Recombinant His-tagged Pfs48/45-6C was diluted into kinetics buffer (PBS, pH 7.4, 0.01% (w/v) BSA, 0.002% (v/v) Tween-20) at 15 μg/mL and immobilized onto Ni-NTA (NTA) biosensors (ForteBio). Following a 60 s baseline step, biosensors were dipped into wells containing twofold dilution series of Fab, from 500 nM to 15.6 nM (affinity measurement). Sensors were then dipped back into kinetics buffer to monitor the dissociation rate. Kinetics data were analyzed using ForteBio’s Data Analysis software 9.0, and kinetic curves were fitted to a 1:1 binding model using at least four concentrations. For experiments with several replicates, the mean kinetic constants reported are the result of two or more independent experiments, and associated error is standard deviation. For RUPA-117 and TB31F Fab binding to 6C.mAgE2 and its glycan variants, association into Fab was performed at 10 μg/mL before being dipped back into kinetics buffer for dissociation. For quantification experiments, TB31F Fab was immobilized on an anti-human Fab CH1 biosensor (ForteBio). 6C.mAgE2 serially diluted in HEK293F supernatant to a concentration range of 0-200 μg/mL was used to generate a standard curve from the association rate. Supernatants of 6C.WT, 6C.sAgE7, 6C.mAgE1, and 6C.mAgE2 from three independent transfections were subsequently characterized. For all quantitation, the initial association slopes were used for calculations, and all analyses were done using ForteBio’s Data Analysis software 9.0 and GraphPad Prism 9.

Circular dichroism
CD thermal melts were conducted at 218 nm, with a temperature ramp of 1 °C per minute, from 20-105 °C, a bandwidth of 2 nm, and a CD scale of 200 mdeg/1.0dOD. For full spectra analysis, samples were analyzed at 190-260 nm in a continuous manner at a rate of 50 nm/min, with a digital integration time (DIT) of 2 s, a bandwidth of 1 nm, and a CD scale of 200 mdeg/1.0dOD. All analyses were first blanked and corrected with PBS, and all samples were tested at a concentration of 0.25 mg/mL.

Dynamic light scattering for extended thermostability analysis
Isothermal DLS was conducted at 25 °C, with 10 acquisitions per measurement, at a 5 s acquisition time. Of the ten acquisitions, reads that differed from the mean initial intensity Autocorrelation were discarded, and a minimum of six acquisitions were used in data processing. Data processing was conducted using the DYNAMICS V7 software, and samples were analyzed in three ranges: 0.1-10 nm, 10-100 nm, and 100-1000 nm. All samples were tested at 1 mg/mL.

Electron microscopy of CoPoP liposomes
6C.mAgE2 CoPoP liposomes containing 40 μg/mL of protein and ~8.4 mg/mL total lipid were diluted five-fold and 3 μL of the sample was deposited on homemade holey gold grids (Marr et al., 2014), which were glow-discharged in air for 15 s before use. Samples were negatively stained with 1% (w/v) uranyl acetate (in ultrapure water) and viewed with a JEOL 1230 transmission electron microscope.
were incubated on a grid for 5 min, blotted for 3.5 s, and subsequently plunge-frozen in liquid ethane (Tivol et al., 2008) using an Automatic Plunge Freezer EM GP2 from Leica (maintained at 4°C and 100% humidity). Data collection was performed with a FEI Tecnai F20 microscope operated at 200 kV with a K2 camera (Gatan Inc). Micrographs were recorded as 15 s movies of 30 frames at 5 electrons per pixel per second and a calibrated pixel size of 1.45 Å per pixel. A defocus range between 2.0 and 3.0 μm was used for data collection.

Negative stain electron microscopy for Pfs48/45-6C-I53-50 particles and controls
Pfs48/45-6C-I53-50 nanoparticles were diluted to 0.03 mg/mL in 50 mM Tris pH 8, 150 mM NaCl, prior to application of 3 μL of sample onto freshly glow-discharged 300-mesh copper grids. The sample was incubated on the grid for 1 min before the grid was dipped in a 50 μL droplet of water and excess liquid blotted away with filter paper (Whatman). The grids were then dipped into 6 μL of 0.75% w/v uranyl formate stain. The stain was blotted off with filter paper, then the grids were dipped into another 6 μL of stain and incubated for ~70 s. Finally, the stain was blotted away, and the grids were allowed to dry for 1 min. Prepared grids were imaged in a Talos model L120C electron microscope at 45,000X magnification.

Animal immunizations with Pfs48/45-6C and Pfs48/45-6C-CoPoP
The immunogenicity of various Pfs48/45-6C constructs was assessed using two different adjuvants (Montanide ISA 720 (SEPPIC) or CPQ liposomes). To prepare the final vaccine, Montanide ISA 720 was mixed with the aqueous antigen at a ratio of 70%/30%. Conversely, CPQ liposomes were simply incubated with the constructs for 3 h at RT. Female ICR mice (Envigo order code 030) were immunized intramuscularly with 5 μg of various Pfs48/45-6C constructs in a prime/boost dose regimen at day 0 and 21; blood was collected at day 42.

Animal immunizations of Pfs48/45-6C nanoparticles and controls
On the day of immunization, immunogens were mixed with AddaVax™ adjuvant from InvivoGen according to the manufacturer’s instructions. For immunizations, 8-week female Crl:CD1(ICR) mice from Charles River Laboratories were anesthetized with isoflurane followed by intramuscular injections into the quadriceps muscle. Each mouse received 0.05 mL of the immunogen in each quadriceps, for a total of 0.1 mL of immunogen per mouse per immunization. Mice were injected on days 0 and 28 for a total of two immunizations. Pre-immune, day 14, and day 42 sera were collected for analysis.

ELISA and SMFA of anti-Pfs48/45 antibodies elicited by Pfs48/45-6C and Pfs48/45-6C-CoPoP at Laboratory of Malaria and Vector Research (LMVR)
The details of ELISA method have been published elsewhere (Miura et al., 2008). All ELISA were conducted using 6C.sAgE7 as a coating antigen. The ability of anti-Pfs48/45 antibodies to reduce the development of P. falciparum NF54 strain oocysts in the mosquito midgut was evaluated by SMFA, as described previously (Miura et al., 2013, 2016; McLeod et al., 2019). In brief, IgG was purified from whole sera using Protein G affinity chromatography, then indicated concentrations of IgG were mixed with 0.15% - 0.2% stage V gametocytemia, and then fed to 3-6-day old female Anopheles stephensi. All experiments were done in the presence of human complement. The mosquitoes were maintained for 8 days and then dissected to count the number of oocysts per midgut in 20 mosquitoes.

ELISA of antibodies elicited by Pfs48/45-6C nanoparticles and controls
50 μL of 2 μg/mL 6C-sAgE7 was plated onto 96-well Nunc Maxisorp (ThermoFisher) plates in TBS. Plates were incubated at 25°C for 1 h then blocked with 200 μL of 2% BSA in TBST for an additional 1 h at 25°C. Plates were washed 3 × in TBST using a plate washer (BioTek). 1:5 serial dilutions of mouse sera were made in 50 μL TBST starting at 1:100 and incubated at 25°C for 1 h. Plates were washed 3 × in TBST, then anti-mouse horseradish peroxidase-conjugated horse IgG (Cell Signaling Technology, #7076S) was diluted 1:2,000 in 2% BSA in TBST and 50 μL was added to each well and incubated at 25°C for 30 min. Plates were washed 3 × in TBST and 100 μL of TMB (SeraCare) was added to every well for 2 min at room temperature. The reaction was quenched with the addition of 100 μL of 1 N HCl. Plates were immediately read at 450 nm on a SpectraMax M5 plate reader (Molecular Devices) and data plotted and fit in Prism (GraphPad) using nonlinear four-parameter logistics sigmoidal regression, where X is log(concentration) to determine EC50 values from curve fits.

SMFA at Radboud University Medical Center (RUMC)
SMFA experiments at RUMC were conducted with Plasmodium falciparum NF54 gametocytes and Anopheles stephensi mosquitoes (Nijmegen colony), as previously described (Ponndurai et al., 1989). Mice sera were diluted in fetal calf serum and mixed with cultured gametocytes, normal human serum with complement and red blood cells. Serum dilution factors indicate the proportion of the total blood meal volume. Negative controls included fetal calf serum only. Blood meals were fed to mosquitoes and 6-8 days later oocysts were counted in 20 fully-fed mosquitoes. Each sample was tested in two independent SMFA experiments. We fitted a mixed-effects negative binomial regression model to model the oocyst counts in each of the test conditions relative to a control. Log risk ratios, that show the log of the relative amount of oocysts in treatment versus control, was directly estimated in the model, and was used to calculate the TRA. Random intercepts were used to account for the correlation between mosquito observations from the same SMFA experiment.
QUANTIFICATION AND STATISTICAL ANALYSIS

To compare ELISA units or ELISA titers, the values were log-transformed, and then a Student’s t-test (to compare two groups) or one-way ANOVA (for more than two groups) followed by Tukey’s multiple comparison tests were utilized.

For SMFA performed at LMVR, the percent of TRA (TRA(%)), the 95% confidence interval (95%CI) and p-value from a single or multiple feeds were calculated using a zero-inflated negative binomial (ZINB) model as before (Miura et al., 2013) for SMFA conducted at LMVR. IC₈₀, IgG concentration which gives 80% TRA, was calculated from a plot where IgG concentration was transformed in a square-root scale and % TRA was transformed in a Log of mean oocyst ratio (LMR) scale, as described previously (Miura et al., 2019).

All statistical tests were performed in Prism 8 or Prism 9 (GraphPad Software, La Jolla, CA, USA) or R (version 3.5.3, The R Foundation for Statistical Computing) and p-values <0.05 are considered significant.